


BioCAD




The CAD for Biological Engineering

We are building the world's first platform to predict morphological outcomes—the shape and structure of animals, cells, and organs—directly from genetic and protein data. We are turning biology from a process of discovery into a discipline of engineering.


Biology's Black Box is Costing Trillions.

For decades, genetic editing has been a gamble. Scientists make changes and hope for the best, unable to predict the final physical outcome (the phenotype) without expensive, lengthy lab work.




Pharma (CAR-T Therapy)

30-50% of manufacturing batches fail, costing **\$400,000-\$500,000** per failed dose.



Agriculture (Livestock)

A decade is lost developing new breeds, with **\$500 million** in annual losses from skeletal defects alone.




Human Fertility (IVF)

There is **no objective method** to predict embryo quality before implantation.

We are operating without a blueprint, and the cost of failure is staggering.

We Provide the Blueprint Before the Build.

BioCAD delivers complete morphological simulation (In-Silico) before the first cell is touched



Stage 1

The system ingests a genetic sequence or protein variant.

Stage 2

We combine foundational protein structure models with our proprietary learning system that maps structural impact on cells.


Stage 3

A predictive, high-fidelity 3D visualization of the resulting organ, cell, or skeleton is generated.

One Core Engine, Infinite Applications.


Our core asset is the **BioCAD Hub**: a central agnostic software architecture that connects molecular biology to physical morphology. This is our defensible moat.

A single, one-time investment in the Hub unlocks entry into six distinct, massive markets with marginal R&D cost.




Skeletal Module (Year 1)

Trained on oVert CT scan data.



Cellular Module (Year 2)

Trained on cell microscopy
data for CAR-T.




Organ Module (Year 3)

Trained on ultrasound and IVF imagery.

A Platform Built for a \$1.01 Trillion Ecosystem.

Total Addressable Market (TAM): **\$1.01 Trillion** across 6 key verticals.



\$49B Market

Our initial entry point.
Low regulation,
immediate data access.

\$65B Market

Our fastest-growing and
most profitable segment,
focused on CAR-T QC.

\$177B Market

A premium frontier with
massive demand and high
willingness to pay.

Phased Market Entry Strategy

Our Strategy: Revenue Before Regulation

We are bypassing the biotech “Valley of Death” and its 7-year FDA wait.

Agriculture

Focus here first. **No FDA regulation** and data is readily available for immediate development and paid pilots.


CAR-T QC (PAT)

Launch Cellular module as a **Process Analytical Technology (PAT)**, not a medical device, for immediate sales **without FDA approval**.

IVF (EU)



Launch in private-pay markets like **Israel and Spain** to build revenue and data before entering the US market.

High-Margin Revenue



A High-Margin B2B SaaS and Licensing Model.

Revenue streams strategically diversified across primary verticals.



Annual Subscription +
Royalties
on improved genetics.




\$100k - \$500k paid pilots
with design partners to fund
initial development.

A Disciplined 3-Year Path to Market Leadership.



The Architects of Biological Engineering

The Visionary Technologist



Josh Reuben (CTO)

- 20+ years in Deep Tech, AI & High-Performance Computing (HPC).
- Former Chief AI Architect at Cognyte.
- MS in Bioinformatics. Expert at the nexus of AI, HPC, and biology.

The Proven Scaler



Or Maman (CEO)


- 15+ years leading global R&D and scaling complex cloud operations at NICE and Cymulate.
- Veteran of elite technological intelligence units.

****Team Structure**:** Lean, capital-efficient core team of 8 based in Israel & Eastern Europe.

We Are Raising a Pre-Seed Round of [INSERT AMOUNT].

We are seeking [INSERT AMOUNT] to achieve the following over the next 18-24 months.

Use of Funds



Outcome

This round funds our path to:

- First enterprise revenue.
- A successful Series A raise.





We Will Design Life,
Not Just Discover It.